Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FMT plus immune checkpoint inhibitors and chemotherapy in previously ICI-treated NSCLC
ChiCTR2500105500Phase 2Not yet recruiting
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Jul 2025
- Modality
- Small Molecules, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of allogeneic fecal microbiota, pemetrexed and gemcitabine in non-small cell lung cancer (NSCLC), sponsored by First Affiliated Hospital of Soochow University. Primary endpoint: Objective Response Rate (ORR). Planned start Jul 2025; status: not yet recruiting.
02
Drugs
allogeneic fecal microbiotapemetrexedgemcitabine
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2500105500.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500105500.